Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Alopecia areata is an unpredictable autoimmune hair loss condition, treated based on severity, with half of patients regrowing hair within a year without treatment.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

Patchy alopecia areata can affect only pigmented hairs, leaving gray hairs untouched.

People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.

Current treatments for Alopecia Areata are unsatisfactory and need improvement.

People with Alopecia Areata often have lower vitamin D levels, and vitamin D supplements might help treat it.

Patients with alopecia areata in Saudi Arabia understand the condition's seriousness but still face significant psychological challenges.

Upadacitinib may cause hair loss.

People with alopecia areata often have lower vitamin D levels than healthy people.

The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.

People with alopecia areata had lower vitamin D levels, but these levels didn't relate to many aspects of the condition.

Homeopathy helped one person with hair regrowth, but more research is needed.

More severe alopecia areata can lower quality of life.

COVID-19 vaccination may be linked to alopecia areata, especially in young adults.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Carcinosin, a homeopathic remedy, helped a young girl with alopecia areata regrow hair and reduce psychological symptoms.

Mothers with alopecia areata have a higher risk of adverse birth outcomes.

Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.

A woman's rare hair loss condition improved on its own, suggesting this type might recover like common cases.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Early-stage Alopecia Areata was effectively treated in less than six months.

Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.

The MPV/PC ratio can help assess disease activity in alopecia areata.

Men with alopecia areata tend to have larger limb and trunk circumferences than healthy men.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.